Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Revenue (2016 - 2025)

Historic Revenue for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $13.8 million.

  • Intellia Therapeutics' Revenue rose 5126.77% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 3351.9%. This contributed to the annual value of $57.9 million for FY2024, which is 5955.07% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Revenue of $13.8 million as of Q3 2025, which was up 5126.77% from $14.2 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Revenue peaked at $28.9 million during Q1 2024, and registered a low of -$1.9 million during Q4 2023.
  • Its 5-year average for Revenue is $11.4 million, with a median of $12.9 million in 2021.
  • As far as peak fluctuations go, Intellia Therapeutics' Revenue surged by 432200.0% in 2022, and later plummeted by 11412.36% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Revenue stood at $12.9 million in 2021, then grew by 5.59% to $13.6 million in 2022, then tumbled by 114.12% to -$1.9 million in 2023, then skyrocketed by 771.57% to $12.9 million in 2024, then rose by 7.05% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $14.2 million for Q2 2025, and $16.6 million during Q1 2025.